Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)

TipRanks20:30

HC Wainwright & Co. : The Mirum Pharmaceuticals (MIRM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $58.00.

HC Wainwright & Co. : The Mirum Pharmaceuticals (MIRM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $58.00.

Zhitong Finance18:40

HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price target.

Benzinga18:38

Mirum Pharmaceuticals Q1 2024 GAAP EPS $(0.54) Misses $(0.48) Estimate, Sales $69.222M Miss $70.171M Estimate

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 32.5 percent increase over losses o

Benzinga04:44

Mirum Pharmaceuticals | 10-Q: Quarterly report

Futu News04:23 · Announcements

Mirum Pharmaceuticals: Volixibat VISTAS and VANTAGE Interim Analyses Scheduled for June

Mirum Pharmaceuticals: Volixibat VISTAS and VANTAGE Interim Analyses Scheduled for June

Dow Jones04:09